Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

about

Raltegravir for the treatment of HIV infection in adults and children Discovery of MK-8970: an acetal carbonate prodrug of raltegravir with enhanced colonic absorption.Raltegravir Once-Daily Tablet: A Review in HIV-1 Infection.

P2860

Q24186953-2CCA469B-6FBF-4487-9943-BF07DA4B6B9A Q41621096-74AE09C7-47FD-49DC-870B-27745EB5A224 Q50086057-827DF234-0896-48E4-8F48-B0C578794975

P2860

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Item

http://www.wikidata.org/entity/Q38166286

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Raltegravir: a review of its u ...... n in children and adolescents.

@en

type

Item

label

Raltegravir: a review of its u ...... n in children and adolescents.

@en

prefLabel

Raltegravir: a review of its u ...... n in children and adolescents.

@en

P1476

Raltegravir: a review of its u ...... n in children and adolescents.

@en

P2860

Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

Pharmacokinetics of antiretroviral therapy in HIV-1-infected children.

Development of antiretroviral resistance in children with HIV in low- and middle-income countries

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.

Raltegravir: in treatment-naive patients with HIV-1 infection.

Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.

Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents.

Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.

P2888

s40272-013-0058-9

P304

91-100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40272-013-0058-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Caroline M Perry

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1013952983

http://www.w3.org/2001/XMLSchema#string

P698

24277175

http://www.w3.org/2001/XMLSchema#string

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

about

P2860

P2860

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

description

name

type

label

prefLabel

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698